Overview
Femasys Q3 sales increased 31.4% yr/yr, driven by FemBloc sales
Company reduced Q3 net loss compared to prior year
Femasys secured $12 mln financing
Outlook
Company expects cash to fund operations into September 2026
Femasys advancing toward U.S. approval of FemBloc
Company expanding FemBloc commercialization in Europe and Asia-Pacific
Result Drivers
FEMBLOC SALES - Sales increase driven by FemBloc, a non-surgical permanent birth control product
REGULATORY APPROVALS - UK and New Zealand approvals expand FemBloc market reach
COST REDUCTION - Decreased R&D expenses due to commercialization and reduced costs
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.10
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Femasys Inc is $6.00, about 86.2% above its November 13 closing price of $0.83
Press Release: ID:nGNX1LQMYg
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
